|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplemental Table 4: Baseline Weight Promoting Medications Combinations by Weight Class** |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
| **Most frequent combinations** | **Underweight** | **Normal Weight**  | **Overweight** | **Class I Obesity** | **Class II Obesity** | **Class III Obesity** | **All women in sample** |
| **(BMI ≤ 18.5)** | **(BMI 18.5-24.9)** | **(BMI 25-29.9)** | **(BMI 30-34.9)** | **(BMI 35- 39.9)** | **(BMI ≥ 40)**  |  |
| **N=910** | **N=31,282** | **N=26,031** | **N=11,554** | **N=4,104** | **N=2,371** | **N=76,252** |
| **Antidep & Antipsych** | 0 0% | 4 0.01% | 4 0.02% | 0 0% | 1 0.02% | 0 0% | 9 0.01% |
| **Antidep & BetaBlock** | 2 0.22% | 172 0.55% | 172 0.66% | 127 1.1% | 49 1.19% | 34 1.43% | 556 0.73% |
| **Antidep & Insulin** | 0 0% | 4 0.01% | 14 0.05% | 15 0.13% | 20 0.49% | 14 0.59% | 67 0.09% |
| **Antidep & Glucocort** | 1 0.11% | 29 0.09% | 35 0.13% | 24 0.21% | 7 0.17% | 1 0.04% | 97 0.13% |
| **BetaBlock & Insulin** | 0 0% | 7 0.02% | 18 0.07% | 18 0.16% | 13 0.32% | 6 0.25% | 62 0.08% |
| **BetaBlock & Glucocort** | 1 0.11% | 24 0.08% | 25 0.1% | 15 0.13% | 8 0.19% | 2 0.08% | 75 0.1% |
| **Insulin & Glucocort** | 0 0% | 2 0.01% | 4 0.02% | 0 0% | 2 0.05% | 1 0.04% | 9 0.01% |